Moderna's mNEXSPIKE shows 35.9% relative effectiveness versus Comirnaty in older adults

Moderna announced published results comparing its mNEXSPIKE COVID-19 vaccine with Comirnaty in 294,499 matched U.S. veterans aged 65 and older. The observational study found mNEXSPIKE was associated with fewer medically attended COVID-19 cases and hospitalizations; an exploratory analysis also linked it to fewer hospitalizations involving major adverse cardiovascular events. The findings do not establish causality, and the predominantly older, male population may limit their applicability to broader populations.